← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	2,131	+54	+3%	$198B
2	2 Danaher DHR $158B	1,898	+77	+4%	$172B
3	3 Novartis NVS $279B	1,081	-39	-3%	$18B
4	4 Illumina ILMN $41B	1,073	+3	+0.3%	$54.6B
5	5 Regeneron Pharmaceuticals REGN $80.1B	1,019	+47	+5%	$54.5B
6	6 Agilent Technologies A $49.1B	943	+58	+7%	$41.5B
7	7 Charles River Laboratories CRL $14.4B	677	+38	+6%	$19.3B
8	8 Revvity RVTY $17B	610	+21	+4%	$17.9B
9	9 DELISTED CATALENT, INC. CTLT	529	+20	+4%	$22.3B
10	10 CRISPR Therapeutics CRSP $4.86B	474	-25	-5%	$4.53B
11	11 ARK Genomic Revolution ETF ARKG $2.05B	470	-44	-9%	$1.75B
12	12 Alnylam Pharmaceuticals ALNY $30B	405	+4	+1%	$21.1B
13	13 Azenta AZTA $1.63B	386	+2	+0.5%	$7.14B
14	14 Guardant Health GH $21.9B	374	-43	-10%	$11.8B
15	15 Intellia Therapeutics NTLA $1.6B	365	+28	+8%	$8.34B
16	NVTA 16 DELISTED Invitae Corporation NVTA	351	-16	-4%	$5.77B
17	17 10x Genomics TXG $9.52B	330	-11	-3%	$11.5B
18	18 Ionis Pharmaceuticals IONS $7.1B	325	-13	-4%	$4.08B
19	19 Editas Medicine EDIT $349M	320	+5	+2%	$2.17B
20	20 Sarepta Therapeutics SRPT $1.78B	307	-24	-7%	$6.08B
21	21 Arrowhead Research ARWR $8.25B	297	-17	-5%	$4.16B
22	22 Bruker BRKR $8.47B	297	+17	+6%	$8.18B
23	23 Fulgent Genetics FLGT $578M	268	+14	+6%	$1.02B
24	24 Fate Therapeutics FATE $232M	265	-7	-3%	$5.67B
25	25 Qiagen QGEN $9.41B	265	+7	+3%	$6.77B